Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



U.K. Trade Balance Non-EU (SA) (Oct)A:--
F: --
P: --
U.K. Trade Balance (Oct)A:--
F: --
P: --
U.K. Services Index MoMA:--
F: --
P: --
U.K. Construction Output MoM (SA) (Oct)A:--
F: --
P: --
U.K. Industrial Output YoY (Oct)A:--
F: --
P: --
U.K. Trade Balance (SA) (Oct)A:--
F: --
P: --
U.K. Trade Balance EU (SA) (Oct)A:--
F: --
P: --
U.K. Manufacturing Output YoY (Oct)A:--
F: --
P: --
U.K. GDP MoM (Oct)A:--
F: --
P: --
U.K. GDP YoY (SA) (Oct)A:--
F: --
P: --
U.K. Industrial Output MoM (Oct)A:--
F: --
P: --
U.K. Construction Output YoY (Oct)A:--
F: --
P: --
France HICP Final MoM (Nov)A:--
F: --
P: --
China, Mainland Outstanding Loans Growth YoY (Nov)A:--
F: --
P: --
China, Mainland M2 Money Supply YoY (Nov)A:--
F: --
P: --
China, Mainland M0 Money Supply YoY (Nov)A:--
F: --
P: --
China, Mainland M1 Money Supply YoY (Nov)A:--
F: --
P: --
India CPI YoY (Nov)A:--
F: --
P: --
India Deposit Gowth YoYA:--
F: --
P: --
Brazil Services Growth YoY (Oct)A:--
F: --
P: --
Mexico Industrial Output YoY (Oct)A:--
F: --
P: --
Russia Trade Balance (Oct)A:--
F: --
P: --
Philadelphia Fed President Henry Paulson delivers a speech
Canada Building Permits MoM (SA) (Oct)A:--
F: --
P: --
Canada Wholesale Sales YoY (Oct)A:--
F: --
P: --
Canada Wholesale Inventory MoM (Oct)A:--
F: --
P: --
Canada Wholesale Inventory YoY (Oct)A:--
F: --
P: --
Canada Wholesale Sales MoM (SA) (Oct)A:--
F: --
P: --
Germany Current Account (Not SA) (Oct)A:--
F: --
P: --
U.S. Weekly Total Rig CountA:--
F: --
P: --
U.S. Weekly Total Oil Rig CountA:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Diffusion Index (Q4)--
F: --
P: --
Japan Tankan Small Manufacturing Outlook Index (Q4)--
F: --
P: --
Japan Tankan Large Non-Manufacturing Outlook Index (Q4)--
F: --
P: --
Japan Tankan Large Manufacturing Outlook Index (Q4)--
F: --
P: --
Japan Tankan Small Manufacturing Diffusion Index (Q4)--
F: --
P: --
Japan Tankan Large Manufacturing Diffusion Index (Q4)--
F: --
P: --
Japan Tankan Large-Enterprise Capital Expenditure YoY (Q4)--
F: --
P: --
U.K. Rightmove House Price Index YoY (Dec)--
F: --
P: --
China, Mainland Industrial Output YoY (YTD) (Nov)--
F: --
P: --
China, Mainland Urban Area Unemployment Rate (Nov)--
F: --
P: --
Saudi Arabia CPI YoY (Nov)--
F: --
P: --
Euro Zone Industrial Output YoY (Oct)--
F: --
P: --
Euro Zone Industrial Output MoM (Oct)--
F: --
P: --
Canada Existing Home Sales MoM (Nov)--
F: --
P: --
Euro Zone Total Reserve Assets (Nov)--
F: --
P: --
U.K. Inflation Rate Expectations--
F: --
P: --
Canada National Economic Confidence Index--
F: --
P: --
Canada New Housing Starts (Nov)--
F: --
P: --
U.S. NY Fed Manufacturing Employment Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing Index (Dec)--
F: --
P: --
Canada Core CPI YoY (Nov)--
F: --
P: --
Canada Manufacturing Unfilled Orders MoM (Oct)--
F: --
P: --
Canada Manufacturing New Orders MoM (Oct)--
F: --
P: --
Canada Core CPI MoM (Nov)--
F: --
P: --
Canada Manufacturing Inventory MoM (Oct)--
F: --
P: --
Canada CPI YoY (Nov)--
F: --
P: --
Canada CPI MoM (Nov)--
F: --
P: --
Canada CPI YoY (SA) (Nov)--
F: --
P: --
Canada Core CPI MoM (SA) (Nov)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
Germany’s recent government shift brings CDU leader Friedrich Merz to power under a fragile coalition with the SPD. Amid rising far-right opposition and EU challenges...
Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 23:49 UTC on May 12, 2025. May 12 (Reuters) - U.S. President Donald Trump signed a broad executive order on Monday directing drugmakers to lower the prices of their prescription drugs to align with what other countries pay.
White House officials said the government will give drugmakers price targets in the next month, and will take further action within six months if the companies do not make "significant progress" toward the goal of lower prices.
Trump has sharply criticised the pharmaceutical industry for years over the price of medicines in the United States. He has also chided other wealthy nations for "freeloading" on U.S. pharmaceutical innovation.
During his first term, in 2017, he accused the industry of "getting away with murder" in the prices they charge the government for prescription drugs.
Trump's proposed international reference pricing program was blocked by a court in 2020.
During his 2024 presidential campaign, Trump said Americans were being overcharged for medicines compared to other nations and pledged to take action.
On Monday, he said he wants to "equalize" prices with other countries by implementing tariffs.
Yes. The U.S. pays the most for prescription medicines in the world, often nearly three times that of other developed nations.
Top-selling blood thinner Eliquis from Bristol Myers Squibb (BMY.N), opens new tab and Pfizer (PFE.N), opens new tab carries a U.S. list price of $606 for a month's supply. The previous administration of Democratic President Joe Biden negotiated that down to $295 for Medicare, which goes into effect in 2026, but the drug costs $114 in Sweden and just $20 in Japan.
Since taking office in January, Trump has reiterated that he wants to end this inequity. On Sunday, he announced on Truth Social that he would sign an executive order to pursue "most favoured nation" pricing.
Also known as international reference pricing, it seeks to narrow the gap between the U.S. and foreign drug prices. Reuters reported in April such a policy was under consideration.
The executive order on Monday differed from what drugmakers had been expecting. Lobbyist sources had told Reuters ahead of the order's signing on Monday that they expected the "most favored nation" pricing to apply to drugs for Medicare patients. But the order appeared to apply to all medicines.
Separately, Trump has also pushed for drugmakers to boost U.S. manufacturing. His administration is conducting an investigation into imports of pharmaceuticals in a bid to levy tariffs on grounds that reliance on foreign production of medicine threatens national security.
Biden's Inflation Reduction Act allows the government to negotiate the price of its most expensive drugs within Medicare.
The prices for the first 10 prescription drugs it negotiated were still on average more than double, and in some cases five times, what drugmakers had agreed to in four other high-income countries, Reuters previously reported.
The industry is strongly opposed to the prospect of dramatically lower drug prices in the United States, the world's largest pharmaceuticals market.
Two industry sources told Reuters last month that any such policy was more concerning to the industry than other potential government moves such as tariffs on imported medicines.
The main U.S. lobby group for drugmakers, the Pharmaceutical Research and Manufacturers of America, known as PhRMA, said, "to lower costs for Americans, we need to address the real reasons U.S. prices are higher: foreign countries not paying their fair share and middlemen driving up prices for U.S. patients."
"Most favored nation is a deeply flawed proposal that would devastate our nation's small- and mid-size biotech companies," said John Crowley, CEO of BIO, the main U.S. trade group for biotechnology companies, in a statement.
Experts warn that referencing prices from other countries is complex, as many drugs sold in the U.S. are not available abroad, and some nations do not publish what they pay for drugs or take years to negotiate prices.
The U.S. does not buy drugs directly for a national health system, as countries such as England and Germany do, instead relying on the private sector to manage drug price negotiations for both government and private health plans.
Analysts said implementing the broad order would be difficult.
The executive order is also likely to face legal challenges, particularly for exceeding limits set by U.S. law, including on imports of drugs from abroad, legal experts said.
Reporting by Maggie Fick in London; Editing by Josephine, Mason, Caroline Humer and Bill Berkrot
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up